Rimonci Capital

TECLens designs and manufactures medical vision-correction devices centered on a corneal crosslinking lens for myopia treatment and related conditions. The core product is a non-invasive therapy worn for about 30 minutes in a clinician’s waiting room, with the eye open or closed, delivering real-time ultrasound sensing and precise prescription tuning to reshape the cornea. The lens operates in a high-oxygen environment and uses scleral positioning to maintain stability during treatment. It aims to address presbyopia, slow progression of myopia in children, and corrections for keratoconus and other refractive errors, potentially reducing long-term reliance on traditional corrective lenses. The company is based in St. James, New York.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.

EyeControl is a medical technology company specializing in innovative communication solutions for healthcare. It develops devices that enable patients, particularly those with limited mobility or speech impairments, to communicate using eye movements. The company's flagship product is an intensive care unit communication device featuring an infrared camera and a connected computer that translates blinks and eye movements into commands.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

NovaSight Ltd, founded in 2016 and based in Israel, is dedicated to advancing pediatric vision care through innovative technology. The company has developed CureSight, an eye-tracking system specifically designed for the treatment of amblyopia in children. This integrated, AI-driven solution allows for precise vision assessments and streamlined treatments, catering to the unique needs and attention spans of young patients. NovaSight aims to prevent vision impairments among children by incorporating data analytics into its medical devices, facilitating novel diagnostic, therapeutic, and preventive approaches in pediatric ophthalmology. The company’s management and advisory board includes seasoned professionals and experts in pediatric vision care, underscoring its commitment to improving eye care for children.

6over6 is a digital healthcare company that has developed a platform allowing users to conduct their own eye vision tests using their smartphones. By integrating essential optometric tools into a mobile application, the company enables users to obtain accurate measurements of refractive errors, which are necessary for eyeglasses and contact lens prescriptions. Their product, GlassesOn, is registered as a Class 1 Exempt Medical Device with the FDA, emphasizing the company's commitment to safety and regulatory compliance. While GlassesOn facilitates effective vision assessment, it does not offer medical advice and is not a substitute for a comprehensive eye health examination. Through this innovative approach, 6over6 aims to enhance accessibility to vision care for a broader audience.

BELKIN Vision is a company focused on developing innovative laser devices to aid healthcare professionals in the treatment of glaucoma. Its products are characterized by being non-invasive, non-contact, instantaneous, painless, and automated, providing effective laser therapy options. The company's mission is to enhance accessibility to first-line drop-less glaucoma care, enabling any ophthalmologist to effectively treat patients. By streamlining the treatment process, BELKIN Vision aims to improve patient outcomes and overall quality of care within the medical community.

EyeYon Medical is an Israeli startup based in Jerusalem, developing innovative medical devices focused on treating corneal edema. The company's flagship product, Hyper-CL, is a hyperosmotic contact lens designed to extract fluids from the cornea through osmosis, improving vision and relieving pain. Additionally, EyeYon Medical has developed DSPEK, an artificial endothelial layer intended to replace injured tissue that can cause corneal edema. Founded by Dr. Daphna Ofer, Dr. Arie Marcovich, and Nahum Ferera, the company operates within the Van Leer Technology Incubator.